Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate

Abstract

Prevalence of hemochromatosis-related symptoms in homozygotes for the C282Y mutation of the HFE gene. Mayo Clinic Proceedings, 77, 522-530.

Chemotherapeutic agents and the skin: An update

“…72,89 One case series of 8 cases of photosensitization in CML patients treated with imatinib has been reported. 90 The only patient with a darker skin type in this series was noted to develop diffuse hypopigmentation in association. It is hypothesized that this phenomenon is not rarer in lighter skin but is instead less noticeable and therefore underreported.…”

Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development ofin vitrohigh-speed screening systems

“…Hematological toxicity was reported in the advanced phase of the disease and is probably related to the dominant Philadelphia chromosome-positive hematopoiesis. The non-hematological adverse events were generally of grade 1 or 2 in severity and included superficial edema, nausea, muscle cramps, and skin rashes [47][48][49][50] . The physiopathology of the skin lesions remains unclear.…”

Small Molecule Multikinase Inhibitors

“…Hair depigmentation is more commonly seen with the kit/PDGF/VEGFR inhibitor sunitinib [3,33]. Moreover, urticaria, neutrophilic dermatosis, vascular purpura [39], pseudolymphoma [40], and photosensitive eruptions have been reported [5,41]. Eruptions and edema seem to be dose dependent [5,7].…”